SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nord who wrote (5462)10/5/1998 10:10:00 PM
From: John Metcalf   of 6136
 
Nord, I was going to claim the title (dufus), but I see I am too late -:)

Rick's point is not what the money did for Chiron, though CHIR shareholders did get $10 per share special dividend (a sign that management did not have better plans for the money). If 49% of Agouron were sold for even a 75% premium to market, which is too low given their independence, Peter Johnson and crew would have $1B to invest above their already substantial R&D.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News